Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
NOVARTIS AG is pushing ahead with one of its most ambitious cancer therapies, a treatment that the Swiss drugmaker says has blockbuster potential as it extends that technology to a wider pool of tumour-ridden patients.
Europe's second-biggest drugmaker is planning to test